Zurich Cantonal Bank
APGE

Zurich Cantonal Bank’s Apogee Therapeutics APGE Stock Holding History

Zurich Cantonal Bank’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,879
Closed -$897K – 2617
2025
Q4 		$897K Buy
+11,879
New +$748K ﹤0.01% 1408

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Zurich Cantonal Bank's APGE Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Apogee Therapeutics (APGE) stake by 21% in Q2 2026, buying an estimated $296K and bringing the position to 19,196 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Zurich Cantonal Bank first reported a position in APGE in Q3 2024 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Zurich Cantonal Bank held 19,196 shares of Apogee Therapeutics worth $2.55M as of Q2 2026.
  • Zurich Cantonal Bank bought 3,280 Apogee Therapeutics shares in Q2 2026, an estimated $296K.
  • Apogee Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #997 holding.
  • Zurich Cantonal Bank first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.